Table 8 cfDNA according to severity (Chinese Center for Disease Control and World Health Organization scales) and mortality and its correlation with interleukin-6 and lactate dehydrogenase (N = samples)
From: IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes
Severity | cfDNA (ng/mL) | p |
|---|---|---|
CCDC scale | < 0.001 | |
Moderate (N = 105) | 6.42 (3.49–10.48) | |
Severe (N = 38) | 7.47 (5.32–13.37) | |
Critical (N = 58) | 14.92 (7.18–24.68) | |
Critical vs. moderate | < 0.001 | |
Critical vs. severe | 0.004 | |
WHO OS | 0.001 | |
Moderate; N = 102 | 6.97 (3.76–10.83) | |
Severe/Critical; N = 99 | 9.36 (5.56–19.60) |
Mortality | cfDNA (ng/mL) | p |
|---|---|---|
Non-survivors N = 39 | 0.021 | |
Viral (1–9 days); N = 17 | 7.87 [5.52–22.38] | |
Early inflammatory (10–16 days); N = 11 | 12.59 [7.88–26.36] | |
Late inflammatory (> 17 days); N = 11 | 30.34 [18.47–39.39] | |
Viral phase vs late inflammatory | 0.031 | |
Survivors N = 141 | 0.328 | |
Viral (1–9 days); N = 70 | 5.98 (3.12–11.45) | |
Early inflammatory (10–16 days); N = 42 | 7.11 (4.59–10.60) | |
Late inflammatory (> 17 days); N = 29 | 7.83 (4.65–12.18) |
Correlation cfDNA with IL-6 and LDH | r | p |
|---|---|---|
IL-6 | ||
Viral (1–9 days) | 0.12, (− 0.104–0.332) | 0.294 |
Early inflammatory (10–16 days) | 0.468 (0.192–0.672) | 0.002 |
Late inflammatory (> 17 days) | − 0.005 (− 0.348–0.339) | 0.977 |
LDH | ||
Viral (1–9 days) | 0.296 (0.079–0.486) | 0.009 |
Early inflammatory (10–16 days) | 0.376 (0.115–0.589) | 0.006 |
Late inflammatory (> 17 days) | 0.294 (− 0.024–0.558) | 0.069 |